ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Sep 2020
Last Updated on 01 Sep 2020
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended listing:
  • Benralizumab and mepolizumab on the Medication Assistance Fund (MAF) for treating severe eosinophilic asthma; and
  • Omalizumab on the MAF for treating severe allergic asthma
due to unacceptable cost-effectiveness at the prices proposed by the manufacturers.


Benralizumab, mepolizumab and omalizumab for treating severe asthma (1 Sept 2020) Benralizumab and mepolizumab for treating severe eosinophilic asthma PES (1 Sept 2020) Omalizumab for treating severe allergic asthma PES (1 Sept 2020)